172 related articles for article (PubMed ID: 38612803)
21.
Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
[TBL] [Abstract][Full Text] [Related]
22. RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.
Ahern E; Harjunpää H; O'Donnell JS; Allen S; Dougall WC; Teng MWL; Smyth MJ
Oncoimmunology; 2018; 7(6):e1431088. PubMed ID: 29872559
[TBL] [Abstract][Full Text] [Related]
23. Transgenic mouse models to study the role of the macrophage scavenger receptor class A in atherosclerosis.
De Winther MP; Gijbels MJ; Van Dijk KW; Havekes LM; Hofker MH
Int J Tissue React; 2000; 22(2-3):85-91. PubMed ID: 10937358
[TBL] [Abstract][Full Text] [Related]
24. Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials.
Chen D; Menon H; Verma V; Guo C; Ramapriyan R; Barsoumian H; Younes A; Hu Y; Wasley M; Cortez MA; Welsh J
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31996395
[TBL] [Abstract][Full Text] [Related]
25. Macrophage scavenger receptor 1 contributes to pathogenesis of fulminant hepatitis via neutrophil-mediated complement activation.
Tang Y; Li H; Li J; Liu Y; Li Y; Zhou J; Zhou J; Lu X; Zhao W; Hou J; Wang XY; Chen Z; Zuo D
J Hepatol; 2018 Apr; 68(4):733-743. PubMed ID: 29154963
[TBL] [Abstract][Full Text] [Related]
26. Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors.
Kaptein P; Jacoberger-Foissac C; Dimitriadis P; Voabil P; de Bruijn M; Brokamp S; Reijers I; Versluis J; Nallan G; Triscott H; McDonald E; Tay J; Long GV; Blank CU; Thommen DS; Teng MWL
Sci Transl Med; 2022 Apr; 14(642):eabj9779. PubMed ID: 35476594
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic control of
Wang MM; Koskela SA; Mehmood A; Langguth M; Maranou E; Figueiredo CR
Front Immunol; 2023; 14():1152228. PubMed ID: 37077920
[TBL] [Abstract][Full Text] [Related]
28. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
Liu D; Schilling B; Liu D; Sucker A; Livingstone E; Jerby-Arnon L; Zimmer L; Gutzmer R; Satzger I; Loquai C; Grabbe S; Vokes N; Margolis CA; Conway J; He MX; Elmarakeby H; Dietlein F; Miao D; Tracy A; Gogas H; Goldinger SM; Utikal J; Blank CU; Rauschenberg R; von Bubnoff D; Krackhardt A; Weide B; Haferkamp S; Kiecker F; Izar B; Garraway L; Regev A; Flaherty K; Paschen A; Van Allen EM; Schadendorf D
Nat Med; 2019 Dec; 25(12):1916-1927. PubMed ID: 31792460
[TBL] [Abstract][Full Text] [Related]
29. Neuroprotective Effect of Phthalide Derivative CD21 against Ischemic Brain Injury:Involvement of MSR1 Mediated DAMP peroxiredoxin1 Clearance and TLR4 Signaling Inhibition.
Zou X; Yang XJ; Gan YM; Liu DL; Chen C; Duan W; Du JR
J Neuroimmune Pharmacol; 2021 Jun; 16(2):306-317. PubMed ID: 32291602
[TBL] [Abstract][Full Text] [Related]
30. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
[TBL] [Abstract][Full Text] [Related]
31. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
32. Triggering MSR1 promotes JNK-mediated inflammation in IL-4-activated macrophages.
Guo M; Härtlova A; Gierliński M; Prescott A; Castellvi J; Losa JH; Petersen SK; Wenzel UA; Dill BD; Emmerich CH; Ramon Y Cajal S; Russell DG; Trost M
EMBO J; 2019 Jun; 38(11):. PubMed ID: 31028084
[TBL] [Abstract][Full Text] [Related]
33. Effect of danhong injection on expressions of macrophage scavenger receptor 1 and sub-family A member 1 in human U937 cells.
Su X; Yang W; Zhi X
J Tradit Chin Med; 2013 Jun; 33(3):384-7. PubMed ID: 24024337
[TBL] [Abstract][Full Text] [Related]
34. Macrophage MSR1 promotes BMSC osteogenic differentiation and M2-like polarization by activating PI3K/AKT/GSK3β/β-catenin pathway.
Zhao SJ; Kong FQ; Jie J; Li Q; Liu H; Xu AD; Yang YQ; Jiang B; Wang DD; Zhou ZQ; Tang PY; Chen J; Wang Q; Zhou Z; Chen Q; Yin GY; Zhang HW; Fan J
Theranostics; 2020; 10(1):17-35. PubMed ID: 31903103
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia-inducible factor-1alpha suppresses the expression of macrophage scavenger receptor 1.
Shirato K; Kizaki T; Sakurai T; Ogasawara JE; Ishibashi Y; Iijima T; Okada C; Noguchi I; Imaizumi K; Taniguchi N; Ohno H
Pflugers Arch; 2009 Nov; 459(1):93-103. PubMed ID: 19641936
[TBL] [Abstract][Full Text] [Related]
36. Sirt6 deletion in bone marrow-derived cells increases atherosclerosis - Central role of macrophage scavenger receptor 1.
Arsiwala T; Pahla J; van Tits LJ; Bisceglie L; Gaul DS; Costantino S; Miranda MX; Nussbaum K; Stivala S; Blyszczuk P; Weber J; Tailleux A; Stein S; Paneni F; Beer JH; Greter M; Becher B; Mostoslavsky R; Eriksson U; Staels B; Auwerx J; Hottiger MO; Lüscher TF; Matter CM
J Mol Cell Cardiol; 2020 Feb; 139():24-32. PubMed ID: 31972266
[TBL] [Abstract][Full Text] [Related]
37. Regulation of MSR-1 and CD36 in macrophages by LOX-1 mediated through PPAR-γ.
Dai Y; Su W; Ding Z; Wang X; Mercanti F; Chen M; Raina S; Mehta JL
Biochem Biophys Res Commun; 2013 Feb; 431(3):496-500. PubMed ID: 23333385
[TBL] [Abstract][Full Text] [Related]
38. Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns.
Gougis P; Hamy AS; Jochum F; Bihan K; Carbonnel M; Salem JE; Dumas E; Kabirian R; Grandal B; Barraud S; Coussy F; Hotton J; Savarino R; Marabelle A; Cadranel J; Spano JP; Laas E; Reyal F; Abbar B
JAMA Netw Open; 2024 Apr; 7(4):e245625. PubMed ID: 38630478
[TBL] [Abstract][Full Text] [Related]
39. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
40. Macrophage scavenger receptor 1 (Msr1, SR-A) influences B cell autoimmunity by regulating soluble autoantigen concentration.
Haasken S; Auger JL; Taylor JJ; Hobday PM; Goudy BD; Titcombe PJ; Mueller DL; Binstadt BA
J Immunol; 2013 Aug; 191(3):1055-62. PubMed ID: 23794629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
